# GLP-1
Latest news and articles about GLP-1
Total: 3 articles found
Chinese Drugmaker Wins FDA Green Light to Test Next‑Generation Obesity Peptide in the US
Shiyao Group has won FDA permission to begin US clinical trials of a long‑acting peptide that acts on both GLP‑1 and GIP receptors for weight management in people with obesity or overweight plus comorbidities. The clearance permits investigational trials but falls short of marketing approval; success would boost China’s ambitions to compete in the lucrative obesity‑drug market dominated by Western firms.
Hengrui’s Oral GLP‑1/GIP Candidate Shows Promising 26‑Week Weight Loss in China — A Potential Game‑Changer for Obesity Care
Hengrui Medicine and Kailera Therapeutics reported positive top‑line results from a 166‑participant Phase II trial of ripubopetide, an oral GLP‑1/GIP dual agonist, showing up to 12.1% mean weight loss at 26 weeks and manageable vomiting rates. Hengrui will pursue Phase III studies in China while Kailera plans a global Phase II in 2026, though larger, longer trials are needed to confirm efficacy and safety.
Wall Street Opens Soft as GLP‑1 Makers Rally and a Generic Challenger Collapses
U.S. markets opened slightly lower as gains in GLP‑1 weight‑loss drug makers were offset by weakness in memory stocks. Novo Nordisk and Eli Lilly rose on continued enthusiasm for semaglutide‑class therapies, while Hims & Hers plunged after facing litigation over a generic version. Micron fell amid renewed pressure on cyclical tech names.